← All candidates
One insider buy in the last year — $98.8K in all.
44 filings on record.
HAEHAEMONETICS CORP
NYSE · Healthcare · $4.64B
$106.31
+3.53% · Sep 14
One insider buy in the last year — $98.8K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$4.64B
Float
44.9M
99% public
Short % float
Pro
Price / profit
49.3
Price / future profit
17.8
Price / sales
3.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Kroll Mark W
Bought $98.8K on Nov 10 — 1,400 sh @ $70.56, held direct, 5.7% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
39 more transactions on Pro →Context
Wall St
$85.20 avg target
-19.9% vs today · 10 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26$1.29 act+$0.02
Q4 '25$1.31 act+$0.06
Q3 '25$1.27 act+$0.16
Q2 '25$1.10 act+$0.08
Coverage
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?Zacks · 07-033 Reasons HAE is Risky and 1 Stock to Buy InsteadStockStory · 06-30A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment RealignmentSimply Wall St. · 06-09Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's NextSimply Wall St. · 05-25
The file stays open
44 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice